Indian generics maker Dr. Reddy's Laboratories ($RDY) will elevate its skills in manufacturing complex injectable drugs with a $35.7 million deal to buy Dutch CDMO OctoPlus. The company says in a release that it is "keen" to move into the fee-for-service business and that OctoPlus' manufacturing and development platform is a perfect fit with Dr. Reddy's marketing abilities. The company pointed to OctoPlus' expertise in injectable specialty generics like liposomes and microspheres. Dr. Reddy's will leave the Dutch contract development and manufacturing organization as a standalone operation and make its operations in Leiden a center of excellence for Dr. Reddy's. It pointed to the Dutch company's ability to improve formulations of new and existing drugs as capabilities Dr. Reddy's will particularly benefit from. The buyout also saves OctoPlus from an uncertain future after Biolex, one of its development partners, filed for bankruptcy. Release | More